-
Lineage's Lead Candidate Used To Treat Patient With Retinal Disease Under Compassionate Use
Monday, March 29, 2021 - 10:15am | 258Read More...Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Inc's (NYSE: LCTX) OpRegen has been used to treat a patient suffering from adult-onset vitelliform macular dystrophy (AVMD) at Hadassah-Hebrew University...
-
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
Monday, March 1, 2021 - 2:11pm | 228Read More...Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) or dry AMD, can lead to blindness caused by damaged and dying...
-
Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder
Wednesday, February 24, 2021 - 8:21am | 221Read More...Following consultations with FDA and European Medical Agency, Opthea NASDAQ: OPT) has finalized trial designs for two Phase 3 clinical trials to assess 2 mg OPT-302, administered 4-weekly or 8-weekly in wet age-related macular degeneration (AMD). Each trial will enroll around...
-
Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD Study
Tuesday, February 16, 2021 - 6:43am | 307Read More...Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retinal diseases. Ocular presented the data at the Angiogenesis, Exudations, and...
-
Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMD
Wednesday, February 10, 2021 - 1:07pm | 154Read More...Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degeneration (AMD) patients with CFH loss-of-function gene variants. The 60-subject trial is...
-
EyePoint Pharma Prices $100M Equity Offering At $11 A Piece
Tuesday, February 2, 2021 - 9:48am | 173Read More...EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has priced its previously announced underwritten public offering of 9.1M common shares at $11/share, raising gross proceeds of $100.1M. The offer price represents a discount of 4% from the last close price of $11.48 on Monday....
-
Why Avalanche Biotechnologies Is Coming Off A Big Day
Thursday, June 11, 2015 - 9:10am | 340Read More...Shares of Avalanche Biotechnologies Inc (NASDAQ: AAVL) closed up more than 7 percent on Wednesday following positive commentary by TheStreet.com. According to author Alfredo Fontanini, the company is approaching an important clinical trial catalyst. Results from a phase IIa study of Avalanche's...
